MONTREAL, QUEBEC--(Marketwire - November 15, 2007) - Thallion Pharmaceuticals Inc. (TSX: TLN) today presented positive safety and efficacy data from the completed Phase I/II trial of ECO-4601 for the treatment of advanced cancer patients. These results support and confirm preliminary results from the dose escalation portion of the study disclosed earlier this year at the annual ASCO meeting. ECO-4601 was safe and well-tolerated up to the maximum dose tested of 480mg/m2/day. Adverse events potentially related to ECO-4601 were nonspecific and common in this type of patient population. Furthermore, in seven refractory cancer patients who had completed six cycles of treatment, six patients achieved stable disease.
